Nov. 8 (Bloomberg) -- Novartis AG said sales of its Tasigna leukemia drug will benefit as patients are able to stop taking it after it has healed them in what the company calls a “path to cure.”
The company is betting on new findings showing that patients who have very little traces of leukemia in their blood can safely stop taking treatments such as Tasigna or Novartis’s best-selling Gleevec cancer drug.
Compared to Gleevec, new clinical data shows that Tasigna more effectively clears patients’ blood, according to a presentation on the company’s website today. These findings will convince more patients to switch from its best-selling drug Gleevec, and will increase the share of new patients taking Tasigna, leading to a “net positive,” according to the slides.
To contact the reporter on this story: Eva von Schaper in Munich at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com